Receiving rapid access to testosterone therapy reduced feelings of gender dysphoria and led to a clinically significant reduction in depression as well as a 50% reduction in suicidality among transgender and gender diverse adults, according to research being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Abcam founder Jonathan Milner opposes Danaher buyout; First Wave tries to find new life in Sanofi drug
Abcam’s founder Jonathan Milner plans to vote against Danaher’s $5.7 billion acquisition of the company, he announced Thursday. Milner owns 6.14% of Abcam. He founded
September 15, 2023